Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

Germany flag Germany · Delayed Price · Currency is EUR
79.00
+0.50 (0.64%)
Last updated: Feb 20, 2026, 8:02 AM CET
Market Cap4.02B +42.0%
Revenue (ttm)724.20M -9.4%
Net Income121.15M -26.6%
EPS2.37
Shares Outn/a
PE Ratio33.16
Forward PE27.04
Dividend0.76 (0.98%)
Ex-Dividend DateJul 14, 2025
Volumen/a
Average Volume14
Open79.00
Previous Close78.50
Day's Range79.00 - 79.00
52-Week Range46.30 - 79.00
Betan/a
RSI79.05
Earnings DateFeb 25, 2026

About FRA:41L

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Industry Pharmaceutical Preparations
Founded 1946
Employees 2,197
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 41L
Full Company Profile

Financial Performance

In 2024, FRA:41L's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements